Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. - Wikidata - wikimedia - TriplyDB

Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases.

Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases.

http://www.wikidata.org/entity/Q37562651

about

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?

P2860

Q36452287-E2672213-6D3A-4207-9FEE-C2C988AE2903 Q37682124-A3A4CAED-47CD-4DF9-84FB-2DEF24DA5717

P2860

Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases.

http://www.wikidata.org/entity/Q37562651

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Extended trastuzumab therapy i ...... otherapy for brain metastases.

@en

Extended trastuzumab therapy i ...... otherapy for brain metastases.

@nl

type

label

Extended trastuzumab therapy i ...... otherapy for brain metastases.

@en

Extended trastuzumab therapy i ...... otherapy for brain metastases.

@nl

prefLabel

Extended trastuzumab therapy i ...... otherapy for brain metastases.

@en

Extended trastuzumab therapy i ...... otherapy for brain metastases.

@nl

P1433

Q37562651-63AA037C-2F8E-4F27-9EB2-0D97CBF60D42

P1476

Q37562651-995769E0-51BA-4806-9944-1B339AB8B5FD

P2093

Q37562651-017C1B2F-8BBE-4D7A-98FE-952DCD04006F

Q37562651-08541756-FF79-4508-B4C5-7D11A321140B

Q37562651-500CAAB3-7A68-49EC-A5D3-B4914ADD4E3F

Q37562651-502B8D64-7A2E-44F7-8E9E-2282F70132F8

Q37562651-6D83F791-CA33-4B86-82A3-23788AD09938

Q37562651-70A85D42-6145-476B-9911-31C04C299FDB

Q37562651-81093201-E868-46CA-B3B2-36C832A79BA6

Q37562651-98F092F3-0840-4B86-911C-880D56F54DEB

Q37562651-C3DE22E4-AF96-45AC-A2B8-57768F9BEC2F

Q37562651-CA8C88A2-6E90-42C8-8DDF-94E151B4EAD4

P2860

Q37562651-04094084-FC1E-4B52-9755-946201AF0614

Q37562651-079D2AEF-135B-42A2-80A6-D1E98DD77BB9

Q37562651-0E2AB131-39FA-445E-9ED2-87AFB75FE546

Q37562651-0EE7F846-24FB-4C8C-AFE2-6A15AD5E4DEB

Q37562651-3270CBF8-0117-4B20-BF86-324E78E56A44

Q37562651-329CF680-FFC2-4EF7-91AE-B9188E5AAD61

Q37562651-3E716741-5124-4CB7-9BCF-5DF71216C0DE

Q37562651-47159A41-B226-4937-B1DD-36C20EF2D792

Q37562651-54CF3D27-431B-4727-9F25-277638F2BCF1

Q37562651-5AD9D41F-A097-461E-AFD1-8DF8C831751F

P304

Q37562651-8B926F26-5DF0-4B70-A934-79DCDEDF6B64

P31

Q37562651-744DCF00-8F95-405D-B6DA-84E0B1704866

P356

Q37562651-30A945F6-6D29-4683-B745-91610DE458BB

P433

Q37562651-F238DF91-E419-4667-BC6B-8C2ED38C634F

P478

Q37562651-A1911250-3B5C-4CA8-BC46-37F5BBAF81D5

P577

Q37562651-FA0200ED-3265-415D-94A1-D585C2F1AC88

P698

Q37562651-00031EB7-2F83-43C1-8871-DEF064E784EE

P921

Q37562651-5BF5CFF5-0377-4C96-BFE5-BBB093E850B3

Q37562651-C7D37125-D5AD-4460-BF46-7E7D2A36886B

P932

Q37562651-E8074EB1-1078-4713-83D5-1A921B4C806B

P356

P1433

Molecular and clinical oncology

P1476

Extended trastuzumab therapy i ...... otherapy for brain metastases.

@en

P2093

Hidemitsu Nakagawa

http://www.w3.org/2001/XMLSchema#string

Hideyuki Arita

http://www.w3.org/2001/XMLSchema#string

Hitoshi Tsuda

http://www.w3.org/2001/XMLSchema#string

Kan Yonemori

http://www.w3.org/2001/XMLSchema#string

Motohiko Maruno

http://www.w3.org/2001/XMLSchema#string

Soichiro Shibui

http://www.w3.org/2001/XMLSchema#string

Takayuki Kinoshita

http://www.w3.org/2001/XMLSchema#string

Tsuyoshi Suzuki

http://www.w3.org/2001/XMLSchema#string

Yasuhiko Tomita

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Fujiwara

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).

Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.

P304

995-1001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2013.162

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24649283

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3916211

http://www.w3.org/2001/XMLSchema#string